SYRE vs VLTO · $7.60B cap vs P/E 29, rev $5.50B
Spyre Therapeutics Inc. (SYRE) versus Veralto Corporation (VLTO) — a side-by-side from cached financials, not a winner call.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Veralto Corporation (VLTO) is a pollution & treatment controls company listed on US.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
Latest reported VLTO revenue for 2025-12-31 was $5.50B. Net income was $940.0M. Revenue was up 6.0% from 2024-12-31 to 2025-12-31. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
SYRE currently screens at market cap $7.60B. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
Not investment advice. Open the SYRE and VLTO stock pages for the full models.
Not investment advice.